CymaBay Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on CymaBay Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date CymaBay Therapeutics Inc Strategy Report
- Understand CymaBay Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
CymaBay Therapeutics Inc (CymaBay), formerly Metabolex Inc is a clinical-stage biopharmaceutical company that develops therapeutics to treat diabetes, liver and other chronic diseases, orphan diseases and related metabolic disorders. The company’s pipeline products comprise Seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd) for the treatment of liver diseases. It also develops MBX-2982 for patients with type 1 diabetes, orphan indications and for various diseases affecting liver functions. The company has collaboration with various pharmaceutical companies and others to develop its product candidates. CymaBay is headquartered in Newark, California, the US.
Headquarters
United States of America
Address
Suite 130, 7999 Gateway Blvd, Newark, California, 94560
Website
www.cymabay.com
Telephone
1 510 2938800
No of Employees
108
Industry
Pharmaceuticals and Healthcare
Revenue (2023)
$31.1M
CymaBay Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Seladelpar (MBX-8025)- Primary Biliary Cholangitis (PBC) |
| Seladelpar- Primary Sclerosing Cholangitis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In February, the company entered into an agreement to be acquired by Gilead Sciences, Inc. for US$4.3 billion. |
| 2023 | Contracts/Agreements | In January, the company entered into an agreement with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of CymaBay’s investigational drug seladelpar for the treatment of primary biliary cholangitis in Japan. |
| 2019 | Regulatory Approval | In February, the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its seladelpar for the treatment of early stage primary biliary cholangitis (PBC) |
Competitor Comparison
| Key Parameters | CymaBay Therapeutics Inc | Gilead Sciences Inc | Zydus Lifesciences Ltd | Intercept Pharmaceuticals Inc | Esperion Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | India | United States of America | United States of America |
| City | Newark | Foster City | Ahmedabad | Morristown | Vero Beach |
| State/Province | California | California | Gujarat | New Jersey | Florida |
| No. of Employees | 108 | 18,000 | 23,026 | 341 | 240 |
| Entity Type | Private | Public | Public | Private | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert J. Wills, Ph.D. | Chairman | Executive Board | 2015 | 69 |
| Sujal Shah | President; Director; Chief Executive Officer | Executive Board | 2017 | 49 |
| Harish Shantharam | Chief Financial Officer | Senior Management | 2023 | - |
| Charles McWherter, Ph.D | President - Research and Development; Chief Scientific Officer | Senior Management | 2022 | 68 |
| Klara Dickinson | Chief - Regulatory and Quality Assurance Officer | Senior Management | 2020 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer